SEC Comment Letter for GSK (GSK) — Sep 8, 2021
GSK plc
Date: Sept. 8, 2021 · CIK: 0001131399 · Accession: 0000000000-21-010915
AI Filing Summary & Sentiment
Letter
United States securities and exchange commission logo September 8, 2021 Iain Mackay Chief Financial Officer GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Re:GlaxoSmithKline plc Form 20-F for the fiscal year ended December 31, 2020 Filed March 12, 2021 File No. 1-15170 Dear Mr. Mackay: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
September 8, 2021
Iain Mackay
Chief Financial Officer
GlaxoSmithKline plc
980 Great West Road
Brentford, Middlesex TW8 9GS
England
Re:GlaxoSmithKline plc
Form 20-F for the fiscal year ended December 31, 2020
Filed March 12, 2021
File No. 1-15170
Dear Mr. Mackay:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences